Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis

Background and Aims: Emitasvir is a new type of hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor, and the data of phase 2 trial has shown emitasvir-sofosbuvir to have good safety and tolerance. We conducted this phase 3 trial to further verify the efficacy and safety. Methods: We ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Huiying, Yang, Xingxiang, Tan, Youwen, Ning, Qin, Yang, Daokun, Wang, Jiefei, Yang, Yongfeng, Zheng, Sujun, Yang, Dongliang, Hou, Jinlin, Xie, Qing, Zhao, Caiyan, Zhang, Lunli, Mao, Xiaorong, Sun, Tong, Bai, Lang, Zhang, Fuchun, Jin, Jinglan, Zhao, Yingren, Wang, Maorong, Xie, Wen, Ma, Yingjie, Quan, Jun, Yan, Xuebing, An, Ping, Lin, Feng, Jia, Jidong, Hu, Xiaoxuan, Gong, Zuojiong, Wu, Jie, Chen, Yongping, Jia, Zhansheng, Lin, Minghua, Wang, Guiqiang, Zhu, Yueyong, Zhang, Yingjun, Xie, Hongming, Luo, Lin, Ren, Qingyun, Huang, Rui, Wei, Lai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562795/
https://www.ncbi.nlm.nih.gov/pubmed/33083247
http://dx.doi.org/10.14218/JCTH.2020.00031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562795/
https://www.ncbi.nlm.nih.gov/pubmed/33083247
http://dx.doi.org/10.14218/JCTH.2020.00031

Ejemplares similares